A monoclonal antibody which inhibits growth of T cell lines

M Nazarea1, Y Saito, S Okazaki

  • 1Department of Medical Chemistry, Faculty of Medicine, Kyoto University, Japan.

In an attempt to elucidate the intricate structure and possibly the signal transduction pathway of the interleukin-2 receptor (IL-2R) we tried to produce monoclonal antibodies against putative human IL-2R-associated molecules which precipitated from YT2C2 cells with a monoclonal antibody (Mik beta 3) against the human IL-2R beta chain. One of the antibodies obtained (7 x A10) recognizes a cell surface molecule of about 120 kDa (p120). Cross-linking of [125I]-IL-2 and immunoprecipitation with 7 x A10 suggest that the p120 protein may somehow associate physically with the IL-2R beta chain. Although p120 itself did not bind IL-2, and 7 x A10 did not inhibit IL-2 binding to the IL-2R, growth of the human IL-2-dependent cell lines ED40515 and Kit225 was completely inhibited by adding 7 x A10 to the culture at a relatively low concentration (0.2 micrograms/ml). At a higher concentration (2 micrograms/ml) 7 x A10 inhibited the growth of YTC3 and YT2C2 cells expressing IL-2Rs with high and intermediate affinities, respectively. The B cell line FLEB-14 and the erythroid cell line K562, which both express p120 as determined by flow cytometry, but no IL-2R alpha or beta chains showed only slight proliferation changes at high 7 x A10 concentrations. Out of 16 lymphocyte cell lines tested so far, only Molt-4, Raji and Daudi did not express p120, and therefore 7 x A10 did not influence their growth behavior.(ABSTRACT TRUNCATED AT 250 WORDS)

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...